StockIQpro
NASDAQ:LSTA

Lisata Therapeutics, Inc.

Track all markets on TradingView
Track all markets on TradingView

Lisata Therapeutics, Inc.'s revenue fell 83.0% in fiscal 2025 to $170,000 while operating margin fell to −10711.2%. Free cash flow was −$16.0M, −9398.2% of revenue, and the diluted share count rose 4.3%.Summary generated from Lisata Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 12, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$170,000
Revenue growth−83.0%
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating margin−10711.2%
Net margin−9756.5%
ROICn/a
Return on equity−74.7%
Debt / equityn/a
Free cash flow−$16.0M
FCF margin−9398.2%
Share count change+4.3%

Financials

Fiscal years, $M
Item20212022202320242025
Revenuen/a0010
Operating income−29−58−26−22−18
Net income−27−54−21−20−17
Free cash flow−22−21−20−19−16

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations